Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs.
Hepatitis A vaccines have demonstrated a high degree of immunogenicity and an excellent safety profile. Immunization of certain populations and patient subgroups is recommended according to specific epidemiological and clinical factors, such as a greater likelihood of acquisition of infection or concerns regarding the risk of development of fulminant hepatitis and death. Therefore, the economic implications of routine and/or targeted vaccination programs in the general population and high-risk individuals have been examined. In this manuscript, the available data from the literature regarding the cost-effectiveness of hepatitis vaccination programs in healthy individuals and in those with chronic liver disease are reviewed.
Deneke
Matthew G
MG
Department of Internal Medicine University Of Alabama at Birmingham, Birmingham, AL 35294, USA.
Arguedas
Miguel R
MR
D003362:Cost-Benefit Analysis; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000191:economics* / Q000276:immunology; D006801:Humans; D017589:Immunization Programs / Q000191:economics / Q000706:statistics & numerical data; D012307:Risk Factors; D014611:Vaccination / Q000191:economics
D022362:Hepatitis A Vaccines